506 filings
8-K
CPRX
Catalyst Pharmaceuticals Inc
21 May 24
Departure of Directors or Certain Officers
5:28pm
8-K
CPRX
Catalyst Pharmaceuticals Inc
8 May 24
Catalyst Pharmaceuticals Reports Solid First Quarter 2024 Financial Results and Provides Business Update
4:54pm
10-Q
2024 Q1
CPRX
Catalyst Pharmaceuticals Inc
Quarterly report
8 May 24
4:06pm
ARS
2023 FY
CPRX
Catalyst Pharmaceuticals Inc
10 Apr 24
Annual report to shareholders
4:25pm
DEF 14A
CPRX
Catalyst Pharmaceuticals Inc
Definitive proxy
10 Apr 24
4:23pm
8-K
uojmh
13 Mar 24
Available in the U.S. by Prescription for Patients Aged Two Years and Older
5:01pm
8-K
nlg0oako68d9bef
28 Feb 24
Catalyst Pharmaceuticals Reports Strong Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
8:37pm
8-K
fw66 81a32
21 Feb 24
Catalyst Pharmaceuticals Announces Publication of Santhera Pharmaceutical’s VISION-DMD
4:34pm
8-K
o305x
9 Jan 24
Catalyst Pharmaceuticals, Inc. Announces Closing of Public Offering of Common Stock
5:15pm
8-K
a68bea 7idzljvu6odxb
8 Jan 24
Regulation FD Disclosure
8:10am
8-K
al5pb5c38vgsbsx9 1ok
5 Jan 24
Catalyst Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
5:23pm
424B5
pdx7qdsvlxt9 m3oa
5 Jan 24
Prospectus supplement for primary offering
5:15pm
424B5
f5v4ssmm5 a5rvh
4 Jan 24
Prospectus supplement for primary offering
6:24pm
8-K
573i42y5pvqrdtj5s2
19 Dec 23
Catalyst Pharmaceuticals Announces FIRDAPSE® New Drug Application Submitted in Japan by Partner DyDo Pharma
4:30pm
S-8
evekb hh2mhbhdck
8 Dec 23
Registration of securities for employees
4:31pm
S-8
npy u60knw
8 Dec 23
Registration of securities for employees
4:31pm
8-K
0c9jpjski3 f2
7 Dec 23
Catalyst Pharmaceuticals Announces Appointment of Michael W. Kalb as Chief Financial Officer and Other Executive Promotions
4:30pm
8-K
xfg175u7vw3xpve33gk
8 Nov 23
Catalyst Pharmaceuticals Reports Strong Third Quarter 2023 Financial Results and Corporate Update
4:35pm